founded in 2000 as a spin-off from the university of tϋbingen in germany, curevac is a leading company in the field of mrna technology and was the first company to start clin-ical trials on mrna-based drugs. the biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. the basic principle of curevac's proprietary technology is the use of mrna as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. the company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. since its inception, strongly backed by sap founder dietmar hopp’s dievini, curevac has received approximately $420 million (€400 million) in equity investments including an investment of the bill & melinda gates foundation of $ 52million in 2015. curevac has entered into various collaborations with multinational corporations and o
Company profile
Ticker
CVAC
Exchange
Website
CEO
Alexander Zehnder
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CureVac B.V.
SEC CIK
CVAC stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
24 Apr 24
6-K
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
24 Apr 24
6-K
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
24 Apr 24
6-K
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
24 Apr 24
6-K
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
16 Apr 24
6-K
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
4 Apr 24
6-K
CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock
17 Jan 24
6-K
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development
5 Jan 24
6-K
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
19 Dec 23
6-K
Current report (foreign)
14 Nov 23
Latest ownership filings
144
Notice of proposed sale of securities
12 Apr 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
GSK plc
6 Feb 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
27 Mar 23
SC 13D/A
Hothum Mathias
24 Feb 23
SC 13D/A
von Bohlen und Halback Friedrich
24 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 92 |
Opened positions | 19 |
Closed positions | 15 |
Increased positions | 32 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 365.18 bn |
Total shares | 236.09 mm |
Total puts | 89.40 k |
Total calls | 149.10 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
KfW | 114.19 mm | $988.89 mm |
dievini Hopp BioTech holding GmbH & Co KG | 70.18 mm | $607.77 mm |
GSK GSK | 14.94 mm | $0.00 |
Ra Capital Management | 12.25 mm | $127.60 bn |
Avidity Partners Management | 4.30 mm | $44.81 bn |
T. Rowe Price | 3.56 mm | $37.26 bn |
Citadel Advisors | 2.35 mm | $24.53 bn |
Millennium Management | 1.88 mm | $19.63 bn |
BLK Blackrock | 1.84 mm | $19.21 bn |
Bill & Melinda Gates Foundation | 1.63 mm | $16.94 bn |
News
Leerink Partners Downgrades CureVac to Market Perform, Lowers Price Target to $4
25 Apr 24
CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza Virus
24 Apr 24
Guggenheim Reiterates Neutral on CureVac
5 Apr 24
CureVac, GSK Partner Release Data On Influenza Vaccine Study
4 Apr 24
CureVac Announces Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
4 Apr 24
Press releases
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
24 Apr 24
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
24 Apr 24
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
24 Apr 24
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
16 Apr 24
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
4 Apr 24